CClinicalTrials.gg
CompletedNCT05655208LANDSCAPEUpdated Mar 29, 2023

Histological Profiles of Lung Allograft Transbronchial Biopsies and Clinical Outcomes After Lung Transplantation

An observational study in Lung Transplant Rejection, sponsored by Paris Translational Research Center for Organ Transplantation. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Paris Translational Research Center for Organ Transplantation · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
498
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Lung transplantation is the only curative treatment for individuals with end-stage lung disease. Understanding the lung allograft's histological lesions, which is key for the patient management, remains difficult because of the multiplicity of lesions associated with graft outcome and their interpenetration.

The goal of this observational study is to identify clusters of histological lesion on transbronchial biopsies in Lung transplant recipient prospective cohort.

The main question[s] it aims to answer are:

  • what are the different pattern of histological lesion?
  • what are the graft outcome associated with the different clusters?
Read the detailed description

SCIENTIFIC JUSTIFICATION:

With more than three million deaths per year, the chronic obstructive pulmonary disease is currently the third cause of mortality worldwide , and contributes to the growing number of individuals with end-stage lung disease, which is now a major issue for world public health. Overall, for individuals with end-stage lung disease, lung transplantation (LTx) is the only treatment able to increase patient survival and quality of life, with more than 4,500 lung transplantations performed each year.

Despite major progresses made in the last decade regarding organ preservation, procurement and short term outcome little improvements have been made on the histological characterization of rejection, which remains the main determinant of patient death after lung transplantation.

One of the main limitation of histological analysis is the multiplicity of lesions associated with graft outcome and their interpenetration. Historically, the perivascular infiltrate or cellular rejection (A lesions), and the lymphocytic bronchiolitis (B lesions) are the first histological lesions associated with graft dysfunction and stand as key parameters in patient management. In addition to A and B lesions, a wide spectrum of histological lesions of the lung allograft is associated with clinical outcomes.

However, to our best knowledge, only few studies thoroughly investigated the various elementary lesions in the broad scope of histological analysis, and their association with clinical outcomes. Although informative, those studies usually suffer from a small number of patients, convenience clinical samples from registry, and the lack of innovative statistical approach. Overall, the wide spectrum of the allograft lesions has not been investigated using a large number of transbronchial biopsies with standardized protocol and biopsy reading, and a multidimensional approach on deeply phenotyped data.

The recent use of unsupervised method in organ transplantation has permitted the identification of clinically relevant patient clusters and may be a relevant strategy to decipher the heterogeneity in histological lesions in lung recipients.

Therefore, using a deeply phenotyped prospective cohort of lung recipients and consecutive transbronchial biopsies with protocolized evaluation and interpretation covering the different cases scenario encountered in clinical practice, the investigators aim to identify histological clusters based on histological lesions and assess their associations with graft and patient outcomes.

OBJECTIVES:

Main objective: To identify of histological cluster of lung allograft Transbronchial biopsies

Secondary objective: To evaluate association of each cluster with baseline clinical data and anti HLA donor specific antibody and graft outcome

INTERVENTIONS:

This is an observational study that involves only minimal risk and constraints. The intervention consists in the evaluation of parameters measured as part of the standard of care at the time of post-transplant allograft biopsy.

No medicinal product is under investigation in this protocol.

EXPECTED BENEFITS for the participants and for society:

There will be no immediate individual benefit for the patient to participate in the study.

This study will provide us with data of Lung transplant patients that may allow the improvement of clinical decisions and the long-term lung allograft management.

MINIMAL RISKS AND CONSTRAINTS added by the study No additional intervention beyond the standard of care will be performed in this study.

RECRUITING CENTER:

  • Single center study
  • Hopital Foch, Suresnes, France
02

Conditions studied

  • Lung Transplant Rejection

Keywords

  • Lung transplantation
  • Rejection
  • Transbronchial biopsy
  • Donor specific Antibody
  • Cluster analysis
03

In context

Lead sponsor

Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This prospective cohort included consecutive lung transplant recipients who were transplanted between February 2010 and November 2019 in Foch Hospital and were eligible for inclusion.

Every protocol and for cause transbronchial biopsies (TBBs) identified in the Foch hospital database for each patient were analyzed using standardized template. Reports of TBB with one or more missing values were excluded. Protocol TBB were performed after transplantation with the following scheme : month 1 (M1) at 30 ± 10 days, month 2 (M2): 60 ± 10 days, month 3 (M3): 90 ± 10 days, month 4 (M4): 120 ± 10 days, month 6 (M6): 180 ± 10 days, month 9 (M9): 270 ± 10 days and month 12 (M12): 365 ± 10 days. For cause TBB were performed in case of graft dysfunction.

Inclusion criteria

  • i) age greater than 18 years,
  • ii) single or bilateral lung transplantation,
  • iii) having at least one transbronchial biopsy available for analysis
  • iv) consent their clinical data to be used for research

Exclusion criteria

Exclusion Criteria:

  • Biopsies with at least one missing value in the standardized clinical report were excluded
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
498 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. graft loss resulting in death or re-transplantation and all-cause mortality

    Time frame: 118 months

Secondary outcomes

  1. chronic lung allograft dysfunction occurrence

    Time frame: 118 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — We will agree to share IPD under reasonnable request and for research purpose only. Any request should be send to Pr Roux Antoine at the following email adress: rouxantoine@hotmail.com

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05655208
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Collaborators
Hopital Foch
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Feb 1, 2010
Primary completion
Nov 30, 2019
Completion
Nov 30, 2019
Last update
Mar 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion